FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324348651> ?p ?o ?g. }

• W2324348651 endingPage "157" @default.
• W2324348651 startingPage "157.1" @default.
• W2324348651 abstract "<h3>Background</h3> An important factor influencing pharmacokinetics of adalimumab is immunogenicity. There is a dose-dependent effect of methotrexate (MTX) on the amount of anti-drug antibodies produced against adalimumab [1]. Consequently, patients concomitantly treated with MTX have higher adalimumab trough levels than patients without concomitant MTX, resulting in a more beneficial clinical response [2]. Whether other disease modifying anti-rheumatic drugs (DMARDs) have a comparable effect on adalimumab levels has not yet been investigated. <h3>Objectives</h3> To investigate the effect of co-treatment with different DMARDs on adalimumab trough levels in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA). <h3>Methods</h3> In this observational cohort study at the Jan van Breemen Research Institute | Reade, Amsterdam a total of 375 consecutive patients (272 RA patients and 103 PsA patients) treated with adalimumab were included. Adalimumab trough concentrations were measured at 0, 4, 16 and 28 weeks of treatment, using an enzyme-linked immunosorbent assay (ELISA). Data was analysed using the General Estimating Equation. Last observation carried forward was used for patients stopping adalimumab therapy prematurely. In addition, in 29 patients the last available drug level before adalimumab dose was increased to 40 mg sc every week was carried forward. <h3>Results</h3> Four groups of adalimumab treated patients were compared: monotherapy (n=67); concomitant MTX (n=224); concomitant other DMARDs (leflunomide, hydroxychloroquine, sulphasalazine or a combination of these) (n=26) and MTX + other DMARDs (n=58). Adalimumab trough levels are shown in figure 1. These levels were significantly higher in patients with concomitant DMARD treatment as compared to monotherapy: monotherapy vs. other DMARDs p=0.011; monotherapy vs. MTX p<0.001; and monotherapy vs. MTX + other DMARDs p<0.001. There was no statistical difference between both MTX groups and the other DMARDs group (p=0.579 [MTX vs. other DMARDs] and p=0.352 [MTX + other DMARDs vs. other DMARDs]). <h3>Conclusions</h3> Adalimumab trough concentrations are the highest in patients concomitantly taking MTX, with or without other DMARDs. Patients on adalimumab monotherapy had the lowest levels. Other DMARDs than MTX also seem to have a beneficial effect on adalimumab trough concentrations, however, these results have to be interpreted carefully, since only 26 patients were included in the “other DMARDs” group. <h3>References</h3> Krieckaert et al. ARD 2012. Pouw et al. ARD 2013 online first. <h3>Disclosure of Interest</h3> C. Krieckaert Speakers bureau: Pfizer, Abbvie, E. Vogelzang: None declared, M. Pouw: None declared, M. Nurmohamed Grant/research support: Abbvie, BMS, MSD, Pfizer, UCB and Roche, Consultant for: Abbott, BMS, Pfizer and Roche, Speakers bureau: AbbVie, Pfizer and Roche., G. Wolbink Grant/research support: Pfizer, Speakers bureau: Pfizer, Amgen <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3618" @default.
• W2324348651 created "2016-06-24" @default.
• W2324348651 creator A5005072175 @default.
• W2324348651 creator A5017243329 @default.
• W2324348651 creator A5018372157 @default.
• W2324348651 creator A5029912678 @default.
• W2324348651 creator A5064804606 @default.
• W2324348651 date "2014-06-01" @default.
• W2324348651 modified "2023-09-25" @default.
• W2324348651 title "OP0252 Adalimumab Serum Concentrations in Patients with Rheumatoid Arthritis or Psoriatic Arthritis Taking Concomitant DMARD Therapy" @default.
• W2324348651 doi "https://doi.org/10.1136/annrheumdis-2014-eular.3618" @default.
• W2324348651 hasPublicationYear "2014" @default.
• W2324348651 type Work @default.
• W2324348651 sameAs 2324348651 @default.
• W2324348651 citedByCount "1" @default.
• W2324348651 countsByYear W23243486512015 @default.
• W2324348651 crossrefType "journal-article" @default.
• W2324348651 hasAuthorship W2324348651A5005072175 @default.
• W2324348651 hasAuthorship W2324348651A5017243329 @default.
• W2324348651 hasAuthorship W2324348651A5018372157 @default.
• W2324348651 hasAuthorship W2324348651A5029912678 @default.
• W2324348651 hasAuthorship W2324348651A5064804606 @default.
• W2324348651 hasConcept C126322002 @default.
• W2324348651 hasConcept C16005928 @default.
• W2324348651 hasConcept C2776260265 @default.
• W2324348651 hasConcept C2777575956 @default.
• W2324348651 hasConcept C2779123688 @default.
• W2324348651 hasConcept C2779134260 @default.
• W2324348651 hasConcept C2779384505 @default.
• W2324348651 hasConcept C2780132546 @default.
• W2324348651 hasConcept C2780564577 @default.
• W2324348651 hasConcept C2781059491 @default.
• W2324348651 hasConcept C3008058167 @default.
• W2324348651 hasConcept C524204448 @default.
• W2324348651 hasConcept C71924100 @default.
• W2324348651 hasConcept C90924648 @default.
• W2324348651 hasConcept C98274493 @default.
• W2324348651 hasConceptScore W2324348651C126322002 @default.
• W2324348651 hasConceptScore W2324348651C16005928 @default.
• W2324348651 hasConceptScore W2324348651C2776260265 @default.
• W2324348651 hasConceptScore W2324348651C2777575956 @default.
• W2324348651 hasConceptScore W2324348651C2779123688 @default.
• W2324348651 hasConceptScore W2324348651C2779134260 @default.
• W2324348651 hasConceptScore W2324348651C2779384505 @default.
• W2324348651 hasConceptScore W2324348651C2780132546 @default.
• W2324348651 hasConceptScore W2324348651C2780564577 @default.
• W2324348651 hasConceptScore W2324348651C2781059491 @default.
• W2324348651 hasConceptScore W2324348651C3008058167 @default.
• W2324348651 hasConceptScore W2324348651C524204448 @default.
• W2324348651 hasConceptScore W2324348651C71924100 @default.
• W2324348651 hasConceptScore W2324348651C90924648 @default.
• W2324348651 hasConceptScore W2324348651C98274493 @default.
• W2324348651 hasIssue "Suppl 2" @default.
• W2324348651 hasLocation W23243486511 @default.
• W2324348651 hasOpenAccess W2324348651 @default.
• W2324348651 hasPrimaryLocation W23243486511 @default.
• W2324348651 hasRelatedWork W2051366753 @default.
• W2324348651 hasRelatedWork W2064564154 @default.
• W2324348651 hasRelatedWork W2083221416 @default.
• W2324348651 hasRelatedWork W2121019867 @default.
• W2324348651 hasRelatedWork W2145093133 @default.
• W2324348651 hasRelatedWork W2324348651 @default.
• W2324348651 hasRelatedWork W2401381953 @default.
• W2324348651 hasRelatedWork W2783320362 @default.
• W2324348651 hasRelatedWork W3005038630 @default.
• W2324348651 hasRelatedWork W3008031868 @default.
• W2324348651 hasVolume "73" @default.
• W2324348651 isParatext "false" @default.
• W2324348651 isRetracted "false" @default.
• W2324348651 magId "2324348651" @default.
• W2324348651 workType "article" @default.